C16 and C17 derivatives of estradiol as inhibitors of 17β-hydroxysteroid dehydrogenase type 1: Chemical synthesis and structure-activity relationships

Drug Design and Discovery

Volumn 15, Issue 3, 1998, Pages 157-180

  Sam, Kay Mane ^a   Boivin, Roch P ^a   Tremblay, Martin R ^a   Auger, Serge ^a   Poirier, Donald ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

17 HSD inhibitors; 17 hydroxysteroid dehydrogenase; Estradiol derivatives; Estrone derivatives; SAR; Steroids; Synthesis

Indexed keywords

ESTRADIOL DERIVATIVE; ESTRONE DERIVATIVE; TESTOSTERONE 17BETA DEHYDROGENASE;

AFFINITY LABELING; ARTICLE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; STRUCTURE ACTIVITY RELATION;

17-HYDROXYSTEROID DEHYDROGENASES; CYTOSOL; ENZYME INHIBITORS; ESTRADIOL; ESTRONE; FEMALE; HUMANS; MOLECULAR WEIGHT; PLACENTA; PREGNANCY; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 0031841053     PISSN: 10559612     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Nicholson, R. I (1993). Recent advances in the antihormonal therapy of breast cancer, Curr. Opin. Invest Drugs, 2, 1259-1268.
2. Coombes, R. C., Goss, P, Dowsett, M., Gazet, J C. and Brodie, A. (1984). 4-hydroxy-androstenedione in treatment of postmenopausal patients with advanced breast cancer, The Lancet, 1, 1237-1239.
3. Brodic, A. M. H. and Santen, R. J. (1994). Aromatase and its inhibitors in breast cancer treatment - overview and perspective, Breast Cancer Res. Treatm., 30, 1-6.
4. Brueggemeier, R. W. (1994) Aromatase inhibitors-mechanisms of steroidal inhibitors, Breast Cancer Res Treatm., 30, 31 -42.
5. Lombardi, P (1995). The irreversible inhibition of aromatase (oestrogen synthetase) by steroidal compounds, Cur. Pharm. Design, 1, 23-50.
6. Penning, T. M. (1996) 17β-hydroxysteroid dehydrogenase: inhibitors and inhibitor design, Endocrine-Related Cancer, 3, 41-56 and references therein.
7. Martel, C., Rhéaume, E., Takahashi, M., Trudel, C., Couet, J., Luu-The, V., Simard, J. and Labrie, F (1992). Distribution of 17β-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues, J. Steroid Biochem. Molec Biol , 41, 597-603.
8. Labrie, F., Luu-The, V., Lin, S. X., Labrie, C., Simard. J., Breton, R. and Belanger, A. (1997). The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology, Steroids, 62, 148-158.
9. Ryan, K. J. and Engel, L. L (1953). The interconversion of estrone to estradiol by human tissue slices, Endocrinology, 52, 287-291.
10. Langer, L. J. and Engel, L. L. (1958). Human placental estradiol-17β-dehydrogenase. I. Concentration, characterization and assay, J. Biol. Chem., 233, 583-588.
11. Chin, C.-C and Warren, J. C. (1975). Synthesis of 16α-bromoacetoxyestradiol 3-methyl ether and study of the steroid binding site of human placental estradiol 17β-hydroxysteroid dehydrogenase, J. Biol. Chem., 250, 7682-7686.
12. Inano, H. and Engel, L. L. (1980). Photoaffinity labeling of human placental estradiol dehydrogenase with 3-(arylazido-β-alanine), J. Biol. Chem., 255, 7694-7699
13. Strickler, R. C., Tobas, B. and Covey, D F. (1981). Human placental 17β-estradiol dehydrogenase and 20α-hydroxysteroid dehydrogenase, J Biol. Chem., 256, 316-321.
14. Murdock, G. L., Warren, J. C. and Sweet, F. (1988). Human placental estradiol 17β-dehydrogenase: Evidence for inverted substrate orientation (wrong-way binding) at the active site, Biochemistry, 27, 4452-4458.
15. +), Biochem. Btophys. Res. Commun , 158, 617-623
16. Ghosh, D. Z., Pletnev, V., Zhu, D. W., Wawrzak, Z., Duax, W. L., Pangborn, W., Labrie, F. and Lin, S. X. (1995). Structure of human 17β-hydroxysteroid dehydrogenase at 220 Á resolution, Structure, 3, 503-513
17. Lin, S. X., Zhu, D. W., Azzi, A., Campbell, R. L., Breton, R., Labrie, F., Ghosh, D., Pletnev, V., Duax, W. L. and Pangborn, W. (1996). Studies on the three-dimensional structure of estrogenic 17β-hydroxysteroid dehydrosenase, J. Endocrinology , 150, S13-S20.
18. Pelletier, J D., Labrie, F. and Poirier, D. (1994). N-butyl, N-methyl, 11-[3',17'β-(dihydroxy)-1'.3',5'(10')-estratrien-16'α-y1]-9(R/S)- bromo undecanamide: synthesis and I7β-HSD inhibiting, estrogenic and antiestrogenic activities, Steroids, 59, 536-547.
19. Sam, K. M., Boivin, R. P., Auger, S. and Poirier, D. (1994). 16α-Propyl derivatives of estradiol as inhibitors of 17β-hydroxysteroid dehydrogenase type 1, Bioorg. Med. Chem Letters, 4, 2129-2132.
20. Tremblay, M. R., Auger, S. and Poirier, D. (1995). Synthesis of 16-(bromoalkyl)-estradiols having inhibitory effect on human placental estradiol 17β-hydroxysteroid dehydrogenase (17β-HSD type 1), Bioorg. Med. Chem., 3, 505-523.
21. Evans, D. D., Evans, D. E., Lewis, G. S., Palmer, P. J. and Weyell, D. J. (1964). Genotropic agents: steroid basic ethers, J. Pharm. Pharmacol., 16, 717-724.
22. 2 and their use as reducing or coupling agents, J. Am. Chem. Soc., 102, 2693-2698.
23. Garrouj, D. E., Aumelas, A. and Borgna, J. L. (1993). Steroidal affinity labels of the estrogen receptor. 1. 17α-(bromoacetoxy) alkyl/alkynylestradiol, J. Med Chem., 36, 2973-2983.
24. Poirier, D., Labrie, C., Mérand, Y. and Labrie, F. (1991). Synthesis and biological activity of 17α-alkylamide derivatives of estradiol, J. Steroid Biochem. Molec. Biol., 38, 759-774
25. Fevig, T. L. and Katzenellenbogen, J. A. (1987). A short stereoselective route to 16α-(substituted-alkyl) estradiol derivatives, J. Org Chem., 52, 247-251.
26. Cox, D. P., Terpinski, J. and Lawrynowicz, W. (1984). "Anhydrous" tetrabutyl-ammonium fluoride: A mild but highly efficient source of nucleophilic fluoride ion, J. Org. Chem., 49, 3216-3219
27. Thomas, J. L., Larochelle, M. C , Covey, D. F. and Strickler, R. C. (1983). Inactivation of human placental 17β, 20α-hydroxysteroid dehydrogenase by 16-methylene estrone, an affinity alkylator enzymatically generated from 16-methylene estradiol-17β, J. Biol Chem , 258, 11500-11504.
28. Ho, T. L (1975) The hard soft acids and bases (HSAB) principle and organic chemistry, Chem. Rev., 75, 1 -21.
29. Salman, M., Reddy, B. R., Ray, S., Stotter, P. L. and Chamness, G. C (1986). 17α-allyI estradiol analogues as candidates for development of high-affinity fluoresceinestradiol conjugates, J. Steroid Biochem., 24, 539-548.
30. Counsell, R. E , Klimstra, P. D., Elton, R. L. and Nutting, E. F. (1966). Chemical and biological properties of some 17-substituted estradiol derivatives, J. Med. Chem., 9, 689-692.
31. Fevig, T L , Mao, M. K. and Katzenellenbogen, J. A. (1988). Estrogen receptor binding tolerance of 16α-substituted estradiol derivatives, Steroids, 51, 471-497.
32. Auger, S., Luu-The, V., Sam, K. M. and Poirier, D. (1994). 3-Hydroxy-19-nor-17α-pregna-1,3,5(10)-triene-21, 17β-carbolactone as inhibitor of 17β-hydroxysteroid dehydrogenase type 2. Bioorg. Med. Chem. Letters, 4, 2045-2048.
33. Sam, K M., Auger. S , Luu-The, V and Poirier, D. (1995). Steroidal spiro-γ-lactones that inhibit 17β-hydroxysteroid dehydrogenase activity in human placental microsomes, J. Med. Chem., 38, 4518-4528